Prime Medicine, Inc.


Offer Price Offer Size 3-Year Outlook Volatility 1st Day Turnover
$17.00 10,300,000 Positive High 26.99%

Offering Team

Deal Managers

  • J P Morgan Chase
  • Goldman Sachs
  • Morgan Stanley


  • Goodwin Procter LLP


  • PricewaterhouseCoopers LLP, or PwC

Pre-IPO Investors


  • Google Ventures
  • Intel Ventures
  • Patricoff Ventures
  • Kleiner Perkins

Pre-IPO Holdings(%)

  • 30
  • 20
  • 05
  • 18

Deal Highlights

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as More

Deal Tracker



19 Oct, 2022


20 Oct, 2022

Look Ahead

Lock Up Expiry

20 Apr, 2023


Nov 1, 2018

IPO Terms

Offer Price $17.00
Offer Size 10M

Market Sentiments

Stock Price